Astrazeneca's lynparza reduces relapse, death in breast cancer patients
- Select a language for the TTS:
- UK English Female
- UK English Male
- US English Female
- US English Male
- Australian Female
- Australian Male
- Language selected: (auto detect) - EN
Play all audios:
In this article * AZN-GB Follow your favorite stocksCREATE FREE ACCOUNT Chris Ratcliffe | Bloomberg | Getty Images AstraZeneca's drug Lynparza reduced the risk of relapse and death in
breast cancer patients with certain mutations in a late-stage trial, the British drugmaker said on Thursday. The results, published in The New England Journal of Medicine, showed that the
drug reduced the combined risk of recurrence of cancer or death from any cause by 42% compared to a placebo. Lynparza, developed with Merck, generated more than $1 billion in sales last year
for AstraZeneca and has become one of the top growth drivers for the drugmaker. The treatment belongs to a class of drugs called PRAP inhibitors that stop cancer cells from repairing
themselves after damage from chemotherapy. In February, the World Health Organization said that breast cancer has overtaken lung cancer as the most common form of the disease and accounts
for nearly 12% of new cases each year worldwide. U.S.-listed shares of AstraZeneca were up 1.33% in extended trading.